Long-acting injectable antipsychotics in first-episode schizophrenia

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Antipsychotic medications are important for the successful management of schizophrenia. Continuous treatment with medication is superior in relapse prevention and non-adherence to antipsychotic medication is associated with a poor clinical outcome. Long-acting injectable antipsychotics (LAIs) that can guarantee adherence to a treatment regimen could be a useful treatment option. With the introduction of second-generation atypical antipsychotics-long acting injection (SGA-LAI), the risks for extrapyramidal adverse events are decreased. The indications for SGA-LAI have been extended from chronic, stabilized patients to acute psychotic patients. Some studies investigated the use of LAI in first-episode schizophrenia patients and raised the possibility of prescribing LAI as a treatment option. However, there is still limited research using LAI in first-episode schizophrenia. More well-designed, randomized, controlled clinical trials using SGA-LAIs in first episode schizophrenia are needed. Additionally, studies on side effects of SGA-LAI in long-term use are required prior to recommending LAI for patients with first episode schizophrenia.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalClinical Psychopharmacology and Neuroscience
Volume11
Issue number1
DOIs
Publication statusPublished - 2013 Apr 1

Fingerprint

Antipsychotic Agents
Schizophrenia
Injections
Cohort Effect
Therapeutics
Secondary Prevention
Randomized Controlled Trials
Research

Keywords

  • Antipsychotic agents
  • Delayed-action preparations
  • Injections
  • Schizophrenia

ASJC Scopus subject areas

  • Behavioral Neuroscience
  • Pharmacology (medical)
  • Psychiatry and Mental health

Cite this

Long-acting injectable antipsychotics in first-episode schizophrenia. / Jeong, Hyun-Ghang; Lee, Moon-Soo.

In: Clinical Psychopharmacology and Neuroscience, Vol. 11, No. 1, 01.04.2013, p. 1-6.

Research output: Contribution to journalArticle

@article{eb02ee909f9e408b8d5d86f65f49f8c9,
title = "Long-acting injectable antipsychotics in first-episode schizophrenia",
abstract = "Antipsychotic medications are important for the successful management of schizophrenia. Continuous treatment with medication is superior in relapse prevention and non-adherence to antipsychotic medication is associated with a poor clinical outcome. Long-acting injectable antipsychotics (LAIs) that can guarantee adherence to a treatment regimen could be a useful treatment option. With the introduction of second-generation atypical antipsychotics-long acting injection (SGA-LAI), the risks for extrapyramidal adverse events are decreased. The indications for SGA-LAI have been extended from chronic, stabilized patients to acute psychotic patients. Some studies investigated the use of LAI in first-episode schizophrenia patients and raised the possibility of prescribing LAI as a treatment option. However, there is still limited research using LAI in first-episode schizophrenia. More well-designed, randomized, controlled clinical trials using SGA-LAIs in first episode schizophrenia are needed. Additionally, studies on side effects of SGA-LAI in long-term use are required prior to recommending LAI for patients with first episode schizophrenia.",
keywords = "Antipsychotic agents, Delayed-action preparations, Injections, Schizophrenia",
author = "Hyun-Ghang Jeong and Moon-Soo Lee",
year = "2013",
month = "4",
day = "1",
doi = "10.9758/cpn.2013.11.1.1",
language = "English",
volume = "11",
pages = "1--6",
journal = "Clinical Psychopharmacology and Neuroscience",
issn = "1738-1088",
publisher = "Korean College of Neuropsychopharmacology",
number = "1",

}

TY - JOUR

T1 - Long-acting injectable antipsychotics in first-episode schizophrenia

AU - Jeong, Hyun-Ghang

AU - Lee, Moon-Soo

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Antipsychotic medications are important for the successful management of schizophrenia. Continuous treatment with medication is superior in relapse prevention and non-adherence to antipsychotic medication is associated with a poor clinical outcome. Long-acting injectable antipsychotics (LAIs) that can guarantee adherence to a treatment regimen could be a useful treatment option. With the introduction of second-generation atypical antipsychotics-long acting injection (SGA-LAI), the risks for extrapyramidal adverse events are decreased. The indications for SGA-LAI have been extended from chronic, stabilized patients to acute psychotic patients. Some studies investigated the use of LAI in first-episode schizophrenia patients and raised the possibility of prescribing LAI as a treatment option. However, there is still limited research using LAI in first-episode schizophrenia. More well-designed, randomized, controlled clinical trials using SGA-LAIs in first episode schizophrenia are needed. Additionally, studies on side effects of SGA-LAI in long-term use are required prior to recommending LAI for patients with first episode schizophrenia.

AB - Antipsychotic medications are important for the successful management of schizophrenia. Continuous treatment with medication is superior in relapse prevention and non-adherence to antipsychotic medication is associated with a poor clinical outcome. Long-acting injectable antipsychotics (LAIs) that can guarantee adherence to a treatment regimen could be a useful treatment option. With the introduction of second-generation atypical antipsychotics-long acting injection (SGA-LAI), the risks for extrapyramidal adverse events are decreased. The indications for SGA-LAI have been extended from chronic, stabilized patients to acute psychotic patients. Some studies investigated the use of LAI in first-episode schizophrenia patients and raised the possibility of prescribing LAI as a treatment option. However, there is still limited research using LAI in first-episode schizophrenia. More well-designed, randomized, controlled clinical trials using SGA-LAIs in first episode schizophrenia are needed. Additionally, studies on side effects of SGA-LAI in long-term use are required prior to recommending LAI for patients with first episode schizophrenia.

KW - Antipsychotic agents

KW - Delayed-action preparations

KW - Injections

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84876947774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876947774&partnerID=8YFLogxK

U2 - 10.9758/cpn.2013.11.1.1

DO - 10.9758/cpn.2013.11.1.1

M3 - Article

C2 - 23678347

AN - SCOPUS:84876947774

VL - 11

SP - 1

EP - 6

JO - Clinical Psychopharmacology and Neuroscience

JF - Clinical Psychopharmacology and Neuroscience

SN - 1738-1088

IS - 1

ER -